Melanoma Molecular Map PROJECT

Great resource on Melanoma


Learn about Melanoma Staging

​​

Last update 12th August 2017 BR

More about Melanoma and Melanoma therapies

Melanoma in short

 

  • Cancer of the skin
  • Detected early, high chances of survival (95% cured). Detected late, fatal prognosis (median survival 6- 9 months without new medicines)
  • 104 000 new cases / year in Europe (Globocan 2012)
  • 22 000 deaths / year in Europe (Globocan 2012)
  • Traditional therapies (surgery, radiotherapy, chemotherapy) limited efficacy once the disease has spread
  • Novel break-through therapies have revolutionized treatment landscape, providing hope for long-term survival for the first time ever. 
  • 8 new therapies plus combinations approved since 2011
  • Patient highly dependent on innovative approaches to development of and access to new therapies

In Europa per year more than

100 000 new cases

22 ooo deathS

due to Melanoma

 

 

(3) Forsea et al., 2012.Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012 Nov;167(5)

(4) Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355:51-65.

(5) National Comprehensive Cancer Network (2010), NCCN clinical practice guidelines in oncology(TM) - melanoma. V.2.2010.

(6) Globocan 2012


Melanoma is a cancer 


that starts from the pigment-producing cells of the body, called melanocytes. Often, Melanoma starts on the skin with a mole but in rarer occasions, it can also start in the eye, on hand and feet or on any inner surface of the body. When Melanoma is discovered at a stage when it has spread, it can become impossible to identify the place where it has started.

Discovered early, Melanomas can be surgically removed and patients have a very high chance of being cured. Once spread, it is sometimes called Malignant Melanoma (although Melanoma is always cancer, so always malignant). Without new medicines, the prognosis is poor, with a survival of 6-9 months after diagnosis. 



the facts


  • At a time, when most cancer incidences are falling, the incidence of Malignant Melanoma is increasing at a rate of 3- 7% in many European countries (1), compared to 2.6% in the US (2).
  • Incidence rates across Europe vary greatly, between 25.8 in Switzerland and 1.3 in Albania for 100 000 Europeans (EUCAN 2012). Please note that the validity of this data strongly relies on the existence of reliable cancer registries which cannot be assumed across Europe (3). The European average of 13/ 100 000 must therefore be considered as unnecessarily optimistic.






































  • Over the last 30 years only, the incidence of Malignant Melanoma hasrisen by 237% (2).
  • Melanoma comprises only 4% of all skin cancers but is responsible for 80% of skin-cancer related deaths (4).
  • Advanced melanoma is the fastest growing malignancy in men and the second-fastest growing in women (5).
  • Every year, more than 100 000 new cases of Melanoma are diagnosed in Europe (6) and more than 22 000 European citizen loose their lives to the disease (6).




Source

(1) Osterlind A. Epidemiology on malignant melanoma in Europe. Acta. Oncol. 1992;31(8):903-8.

(2) SEER, NCI



Melanoma- the facts


information on melanoma


​​A very complete ASCO guide to Melanoma written for patients and particularly interesting for patients with metastatic Melanoma as it covers the latest therapy options thoroughly.

Sections are regularly reviewed and approved by theCancer.Net Editorial Board, mostly 9/2013.

written for patients


by the american society of clinical oncology


Surviving Melanoma in Europe.  

Access to prevention, early detection and effective treatment for all.

Melanoma Patient Network Europe

The melanoma portal 

of the American Society of Clinical Oncology

ADvanced


read what your oncologist is reading